A study of Tocilizumab in patients with JIA associated Uveitis who have not responded to treatment with an anti-TNF.
- Conditions
- Juvenile Idiopathic Arthritis with Associated UveitisMedDRA version: 18.0 Level: PT Classification code 10046851 Term: Uveitis System Organ Class: 10015919 - Eye disordersMedDRA version: 18.0 Level: PT Classification code 10059176 Term: Juvenile idiopathic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- EUCTR2015-001323-23-GB
- Lead Sponsor
- niversity Hospitals Bristol NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 21
1)Children and young people aged = 2 and <18 years fulfilling ILAR diagnostic criteria for JIA (all subgroups that have uveitis).
2)At the time of trial screening the participant must have active anterior uveitis, defined as a sustained grade of cellular infiltrate in anterior chamber of SUN criteria grade =1+ or more during the preceding 6 weeks treatment.
3)Participants must have failed MTX (minimum dose of 10mg/m2, with a maximum dose of 20mg/m2 and not to exceed 25mg/participant) The participant must have been on MTX for at least 12 weeks and have been on a stable dose of MTX for 4 weeks prior to screening visit.
4)Participants must have failed an anti TNF agent (including etanercept, infliximab, golimumbab, certolizumab pegol or adalimumab) and have been on at least one anti-TNF agent regardless of dose for at least 12 weeks at any time previously.
5)If a patient has received previous treatment with any of the following biologic agents, these must have been discontinued according to the following timelines prior to registration:
Infliximab 8 weeks prior to registration.
Etanercept 2 weeks prior to registration.
Adalimumab 4 weeks prior to registration.
Abatacept 8 weeks prior to registration.
Canakinumab 20 weeks prior to registration.
Rilonacept 6 weeks prior to registration.
Anakinra 1 week prior to registration
If a patient has been on another biologic agent not listed above then please contact the trial team for appropriate washout period
6)Written informed consent of participant or parent/legal guardian, and assent where appropriate.
7)Participant and parent/legal guardian willing and able to comply with protocol requirements.
8)For participants of reproductive potential (males and females), use of a reliable means of contraception throughout their trial participation (abstinence is an acceptable method of contraception as long as this is the usual and preferred lifestyle of the patient.)
9)Post pubertal females must have a negative serum pregnancy test within 10 days prior to registration.
10)Able to commence trial treatment within 2 weeks of the screening visit.
Are the trial subjects under 18? yes
Number of subjects for this age range: 22
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 0
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0
1)Uveitis without a diagnosis of JIA
2)Currently on Tocilizumab or has previously received Tocilizumab.
3)Participation in another clinical trial of investigational medicinal product within the last 4 weeks or 5 serum half-lives (whichever is longer)
4)More than 6 topical steroid eye drops per day per eye at time of screening
5)For patients on Prednisone or Prednisone equivalent, change of dose within 30 days prior to registration
6)For patients on Prednisone or Prednisone equivalent with a dose >0.2mg/kg per day
7)No intraocular injection of disease modification agents including steroids and anti-VEGF within 6 months prior to registration.
8)No intraocular surgery for previous 12 weeks or expected/panned for duration of study.
9)Lack of recovery from recent surgery or surgery < 6 weeks at the time of registration
10)Intra-ocular pressure = 25mm Hg at time of screening.
11)On anti-glaucoma medications
12)No disease modifying immunosuppressive drugs, other than MTX in the 4 weeks prior to registration
13)History of active tuberculosis of less than 6 months treatment or untreated latent TB (a test for latent tuberculosis infection (LTBI) must be performed within twelve weeks prior to registration.
14)Latent TB not successfully treated for at least 4 weeks prior to registration
15) Auto-immune, rheumatic disease or overlap syndrome other than JIA.
16)Females who are pregnant, lactating, or intending to become pregnant during trial
17)Known human immunodeficiency virus infection or other condition characterized by a compromised immune system
18)Any history of alcohol or drug abuse within 6 months prior to registration
19)Any active acute, sub-acute, chronic, or recurrent bacterial, viral, systemic fungal, infection or any major episode of infection requiring hospitalisation or treatment with IV antibiotics within 4 weeks of registration or treatment with oral antibiotics within 2 weeks of registration
20)History of reactivation or new onset of a systemic infection such as herpes zoster or Epstein-Barr virus within 2 months prior to registration
21)Hepatitis B surface antigen or hepatitis C antibody positivity or chronic viral or autoimmune hepatitis
22)History of concurrent serious gastrointestinal disorders
23)Evidence of current serious uncontrolled concomitant cardiovascular (including hyperlipidemia), nervous system, pulmonary (including obstructive pulmonary disease), renal and hepatic disease
24)History of or current cancer or lymphoma
25)Persistently poorly controlled severe hypertension (>95th percentile for height / age)
26)Uncontrolled diabetes mellitus
27)History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
28)No live attenuated vaccines (including seasonal nasal flu vaccine, varicella vaccine for shingles or chickenpox, MMR or MMRV, oral polio vaccine and vaccines for yellow fever, measles, mumps or rubella) 4 weeks prior to registration, throughout the duration of the trial and for
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method